CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
CervoMed Inc CRVO
$2.54
▲ +0.79%
(+$0.02)
⬆️ Above Yest. High
🎈 Low Float
Open
$2.52
Prev Close
$2.52
Day Range
$2.52 – $2.63
52W Range
$2.13 – $10.00
Market Cap
$38.40M
Beta
-0.64
EPS (TTM)
$-3.21
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-11-09 |
| Shares Out. | 13,530,000 |
| Website | cervomed.com/ ↗ |
| Phone | 16177444400 |
| Employees | 15 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$6.6M |
| Free Cash Flow | -$28.0M |
| Total Assets | $26.0M |
| Total Liabilities | $3.0M |
| Equity | $23.0M |
About CervoMed Inc
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
CervoMed Inc is a publicly traded company under the ticker symbol CRVO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)